Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Lowering Blood Pressure May Prevent New Brain Lesions in Older PeopleBladder Drug Can Cause Eye Damage: StudyGood News, Bad News on Concussions in High School SportsSteroid Shots for Painful Joints May Make Matters WorseHealth Tip: Broken Toe CareChildhood Risk Factors Can Predict Adult ObesityHealth Tip: Gum Disease Risk FactorsPut Safety First When Planning to Pack Food-to-GoA Parent's Guide to Managing Kids' Asthma During the FallVision Problems Strike More Than 2 Billion GloballyLight Smoking Causes More Lung Damage Than Once Suspected: StudyHealth Tip: Choking First AidBy Mid-Century, Heat Waves Could Cover Far Bigger AreasGet Vaccinated Before Flu Takes Hold: CDCClose to 1,300 Cases of Vaping-Linked Illness Now IdentifiedMore Years of Football, Higher Odds for Brain Disease LaterPain Relief: When to Use Cold, When to Use HeatAHA News: High Triglycerides Caused a Diet Change – at Age 10Humans May Possess Ability to Regrow CartilageHealth Tip: Recognizing Bedbug Bites'Smartphone Slouching' More Serious Than It SoundsAHA News: What's Your Sense of Purpose? The Answer May Affect Your HealthDeep Brain Stimulation May Relieve Ringing in the Ears: StudyWhat Are the Risks of Pain Relief Alternatives to Opioids?Many ICU Admissions May Be Preventable, Large Study SuggestsCause of Paralyzing Illness in Kids Remains ElusiveFlu Season Is Coming: Here's How to Protect YourselfSinus Infections: What You Need to KnowFewer Teeth, Higher Risk of Heart Disease?Fungal Invasion May Drive Some Pancreatic CancersHealth Tip: Lowering Your Resting Heart RateCan Your Eating Habits Keep Alzheimer's at Bay?Prescription Opioids Linked to Poor Outcomes in Kidney PatientsCases of Serious Vaping-Linked Lung Injury Now Top 1,000Organic Chicken Less Likely to Harbor a Dangerous 'Superbug'Running the Numbers on High Blood PressureIs Partial Hip Replacement Often the Better Option?'Toxic Fumes' May Be Driving Vaping-Linked Lung Illnesses'Nerve-Release' Surgery Helped Ease One Man's Tough MigrainesCould Vitamin C Infusions Save Patients With Sepsis?Some May Be Vulnerable to Severe Skin Reaction While Using Gout DrugThree-Drug Inhaler May Be an Advance for Asthma PatientsCab Drivers Breathe in Way Too Much Smog'Alarming' Number of Lupus Patients Use Opioids for Pain: StudyChildhood TB Shot May Offer Long-Term Protection from Lung CancerMavyret Approved as 8-Week Treatment for Hep C, Compensated CirrhosisMany Americans With Rheumatic Disease Face Financial, Lifestyle PressuresRadiation for Head and Neck Cancer May Cause Problems Years LaterHealth Tip: Reducing EyestrainSticking to One Sport Could Up Injuries Among Teen Athletes
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

New Migraine Drug Might Help When Other Meds Don't

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Jul 10th 2019

new article illustration

WEDNESDAY, July 10, 2019 (HealthDay News) -- A new migraine drug might offer an alternative to people who do not get relief from current medications, a new trial suggests.

The drug, called rimegepant, hasn't yet been approved by the U.S. Food and Drug Administration. But it belongs to a new class of drugs that has come to the market within the past year -- known as CGRP inhibitors.

CGRP is a small protein that is released by the trigeminal nerve during migraine attacks, research shows. It's believed to play a key role in generating migraine misery.

The three CGRP inhibitors that are already approved by the FDA are all injected drugs that are used regularly to prevent migraine attacks.

But rimegepant is different because it's an oral medication that treats migraines in progress, explained lead researcher Dr. Richard Lipton.

His team found that among nearly 1,200 migraine patients, the drug outperformed inactive placebo tablets. About 20% of patients who used one dose of rimegepant were pain-free within two hours, compared with 12% of placebo users.

Many other patients, while not pain-free, still got relief, said Lipton, who directs the Montefiore Headache Center at Albert Einstein College of Medicine in New York City.

He is also a paid consultant to rimegepant developer Biohaven Pharmaceuticals, which funded the trial. The findings are published in the July 11 issue of the New England Journal of Medicine.

In the United States alone, over 37 million people suffer from migraines, according to the American Migraine Foundation. The headaches cause severe pain, and often additional symptoms such as sensitivity to light and sound, nausea and visual disturbances.

People with milder migraines may find general pain relievers like naproxen and acetaminophen are enough, according to the foundation. For more severe attacks, there are "migraine-specific" drugs called triptans, which target the brain chemical serotonin.

Triptans have been used for decades, but they don't help everyone, Lipton said. They also have side effects -- like numbness, dizziness and sleepiness -- that can make them difficult to take.

Beyond that, triptans constrict the blood vessels, and people at high risk of heart attack or stroke cannot use them.

If approved, Lipton said, rimegepant would offer a new option for those patients.

It would not, however, replace triptans, which are available as low-cost generics. For "very reasonable economic reasons," Lipton said, they'll still be the first choice for acute migraine treatment.

Dr. Rachel Colman is an assistant professor of neurology at Mount Sinai's Icahn School of Medicine in New York City. She wasn't involved with the study, but reviewed the findings.

Colman agreed that an alternative for treating migraines would be welcome. "There's a significant need," she said, "and it would be wonderful to have an additional option that's a targeted agent."

The trial included 1,186 adults with migraines that struck two to eight times per month, and were moderate to severe in intensity. About half were randomly assigned to take one dose of rimegepant the next time they had a migraine; the other half were given an identical-looking placebo tablet.

Patients used electronic diaries to rate their symptoms before and after taking the tablet.

Overall, the real drug was more effective in erasing, or at least easing, pain within two hours. Of rimegepant users, 58% said their pain had dissipated, versus 43% of placebo users.

Patients also rated their "most bothersome" symptom -- whether it was pain, nausea or sensitivity to light or sound. Just under 38% of rimegepant users were free of their most bothersome symptom within two hours. That compared with 25% of placebo users.

As for safety, Colman said the findings were "reassuring." After a single dose, just under 2% of rimegepant patients had nausea, and 1.5% developed a urinary tract infection.

There are still questions, though, Colman said. "This trial looked at a single treatment," she noted. "Does the drug continue to be effective over time? Consistency is important."

It would also be helpful, Colman said, for studies to focus on patients who'd failed to benefit from triptans, or who cannot take the drugs.

A separate trial in the same journal focused on cluster headaches -- a rare disorder that affects about 0.1% of the population. It causes daily bouts of intense pain for a period of weeks to months at a time.

The trial, of 106 patients, tested a new injection drug called galcanezumab, meant to prevent cluster headaches. In the three weeks after one injection, patients suffered about nine fewer headaches per week -- versus five fewer among patients given a placebo injection.

The researchers, led by Dr. Peter Goadsby of King's College London in England, said larger, longer studies are needed to see if the benefit holds up.

More information

For more facts and resources for migraines, visit the American Migraine Foundation.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net